Impact Factor
4.24
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.79
3,530 total citations
h5-index
64
h5 depth signal
Cited share
88.4%
683 of 773
Total citations
3,530
Citation footprint
Metric signal
5.65
External metric anchor
Self-citation
5.9%
208 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
3,478
China
909
United Kingdom
584
France
547
Spain
436
Citing Fields of Research
Antibiotic & Antibacterial Agents
3,805
Bacteriology
1,888
Fungal Pathogenesis
915
Mycobacterial Diseases
815
Parasitology Studies
623
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
33,603
Articles tracked across the journal lifetime
Indexed publication set
773
683 cited publications
Last 12 months
518
43.2 publications/month
Open access share
100.0%
518 OA publications in the last year
Leading citing country
United States
3,478 citing publications
Leading citing field
Antibiotic & Antibacterial Agents
3,805 citing publications
Latest tracked publication
14 October 2026
10 recent records available
Coverage & Indexing History
v1, 1972-
v1, 1972-
Active Coverage
Active Coverage
Research Focus & Classification
Indexed Subjects
Antibiotic & Antibacterial Agents
Issuing & Sponsoring Bodies
Contributor
American Society for Microbiology
Broad Categories
Anti-Infective Agents
Antibiotic & Antibacterial Agents
Mycobacterial Diseases
Fungal Pathogenesis
Parasitology Studies
MeSH Descriptors
Anti-Bacterial Agents
Antiviral Agents
Drug Therapy
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1128/aac.01049-26
Open DOI
Pharmacokinetic/pharmacodynamic evaluation of multidose oritavancin for prolonged durations of therapy
Managing multidrug-resistant gram-positive infections is challenging, especially when prolonged therapy is needed for conditions like bacteremia, endocarditis, osteomyelitis, or other deep-seated infections. Oritavancin, a long-acting li...
02
DOI 10.1128/aac.00986-26
Open DOI
Population pharmacokinetics of piperacillin based on multicenter data to support model-informed precision dosing in critically ill women
Sex-specific differences in pharmacokinetics are increasingly recognized as clinically relevant, yet most population pharmacokinetic models for antibiotics have been developed in predominantly male populations with limited transferabilit...
03
DOI 10.1128/aac.01089-26
Open DOI
A machine learning framework for precision dosing of daptomycin across diverse disease states
The large pharmacokinetic variability of daptomycin across disease states poses a challenge for individualized dosing. Conventional population pharmacokinetic (PopPK) models are often limited to specific conditions, lacking generalizabil...
04
DOI 10.1128/aac.00825-26
Open DOI
In vitro in-depth characterization of emodepside in combination with key anthelmintic drugs on soil-transmitted helminths
Despite the enormous disease burden, treatments are limited for soil-transmitted helminthiasis. The handful of anthelmintic drugs suffer from variable and often insufficient efficacy against the pathogens. Resistance development, caused ...
05
DOI 10.1128/aac.01070-26
Open DOI
Efflux reprogramming promotes Staphylococcus aureus persistence with Pseudomonas aeruginosa in cystic fibrosis
Staphylococcus aureus persists in cystic fibrosis (CF) airways despite in vitro antibiotic susceptibility, suggesting that efflux reprogramming driven by environmental and polymicrobial interactions with Pseudomonas aeruginosa promotes s...
06
DOI 10.1128/aac.00676-26
Open DOI
Open-label Phase 1 study to evaluate drug-drug interactions between ulonivirine and islatravir in adults without HIV
Ulonivirine is a non-nucleoside reverse transcriptase inhibitor in clinical development for once-weekly oral treatment of HIV-1 in combination with islatravir. This open-label, 3-period, Phase 1 study (MK-8507-016, NCT06619678) in adults...
07
DOI 10.1128/aac.00549-26
Open DOI
A gene network regulating echinocandin heteroresistance in Candida glabrata
While pathogenic fungi can acquire resistance to the current arsenal of antifungals through genetic mutations, heteroresistance has emerged as an important new cause of therapeutic failures. Heteroresistance is generally thought to arise...
08
DOI 10.1128/aac.00562-26
Open DOI
Population pharmacokinetics modeling of albendazole and its active metabolite, albendazole sulfoxide in mass drug administration against lymphatic filariasis
Albendazole (ALB), a benzimidazole antiparasitic, is widely used in mass drug administration (MDA) campaigns against lymphatic filariasis (LF). It is rapidly metabolized to its active form, albendazole sulfoxide (ALB-OX), which exhibits ...
09
DOI 10.1128/aac.00900-26
Open DOI
Development and validation of a cefepime population pharmacokinetic model to guide treatment for patients with hospital-acquired pneumonia requiring renal replacement
Cefepime is used in critically ill pneumonia patients, but dosing in renal replacement therapy (RRT) is complicated by altered renal function, extracorporeal removal, and variability in pulmonary epithelial lining fluid (ELF) exposure. W...
10
DOI 10.1128/aac.00434-26
Open DOI
Modeling the potential effect of cabamiquine-pyronaridine for chemoprevention against Plasmodium falciparum malaria
Preventive treatment (chemoprevention) is a key intervention for reducing the burden of Plasmodium falciparum malaria in children. The impact of the current widely used drug combination, sulfadoxine-pyrimethamine-amodiaquine (SP-AQ), is ...
Bibliographical & Catalog Notes
Print issues ceased with v. 58 (2014).
Also issued online.
Cumulated annually on CD-ROM with same title; also available as part of ASM journals on CD.
Vol. 26, no. 5 (NOV 1984)19900924 Notice published Printed on acid-free paper